Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol

INTRODUCTION: End-stage kidney disease (ESKD) is a major public health problem affecting more than 2 million people worldwide. It is one of the most severe chronic non-communicable diseases. Haemodialysis (HD) is the most common therapeutic option but is also associated with a risk of cardiovascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Blankestijn, Peter J, Fischer, Kathrin I, Barth, Claudia, Cromm, Krister, Canaud, Bernard, Davenport, Andrew, Grobbee, Diederick E, Hegbrant, Jörgen, Roes, Kit C, Rose, Matthias, Strippoli, Giovanni FM, Vernooij, Robin WM, Woodward, Mark, de Wit, G Ardine, Bots, Michiel L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Renal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044930/
https://www.ncbi.nlm.nih.gov/pubmed/32029487
http://dx.doi.org/10.1136/bmjopen-2019-033228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044930/
https://www.ncbi.nlm.nih.gov/pubmed/32029487
http://dx.doi.org/10.1136/bmjopen-2019-033228

Ejemplares similares